CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Biomerieux - BIM CFD

    99.40
    1.19%
    0.45
    Low: 98.8
    High: 100.5
    Market Trading Hours* (UTC) Opens on Wednesday at 08:00

    Mon - Fri: 08:00 - 16:30

    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.45
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.022082 %
    Charges from full value of position ($-4.20)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.022082%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.00014 %
    Charges from full value of position ($-0.03)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.00014%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency EUR
    Margin 5%
    Stock exchange France
    Commission on trade 0%

    *Information provided by Capital.com

    Biomerieux SA ESG Risk Ratings

    High Medium Low Negligible

    ‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 100.6
    Open* 100.5
    1-Year Change* 1.77%
    Day's Range* 98.8 - 100.5
    52 wk Range 84.54-102.60
    Average Volume (10 days) 66.45K
    Average Volume (3 months) 1.97M
    Market Cap 11.50B
    P/E Ratio 29.86
    Shares Outstanding 118.12M
    Revenue 3.70B
    EPS 3.26
    Dividend (Yield %) 0.87449
    Beta 0.03
    Next Earnings Date Mar 6, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 5, 2023 99.40 -0.60 -0.60% 100.00 100.70 98.65
    Dec 4, 2023 100.60 0.60 0.60% 100.00 101.35 99.90
    Dec 1, 2023 100.35 1.55 1.57% 98.80 100.50 98.50
    Nov 30, 2023 98.60 0.20 0.20% 98.40 98.85 96.90
    Nov 29, 2023 98.75 0.35 0.36% 98.40 99.40 98.05
    Nov 28, 2023 98.70 0.60 0.61% 98.10 98.75 97.40
    Nov 27, 2023 98.40 0.05 0.05% 98.35 99.25 98.15
    Nov 24, 2023 98.10 0.50 0.51% 97.60 98.20 97.00
    Nov 23, 2023 98.10 1.45 1.50% 96.65 98.15 96.20
    Nov 22, 2023 96.80 0.85 0.89% 95.95 97.00 95.25
    Nov 21, 2023 95.55 -0.05 -0.05% 95.60 95.85 94.95
    Nov 20, 2023 95.70 0.30 0.31% 95.40 96.10 94.15
    Nov 17, 2023 95.80 0.50 0.52% 95.30 96.60 95.30
    Nov 16, 2023 95.70 -0.80 -0.83% 96.50 96.95 95.65
    Nov 15, 2023 96.55 -0.25 -0.26% 96.80 98.00 96.00
    Nov 14, 2023 97.20 3.10 3.29% 94.10 97.90 93.90
    Nov 13, 2023 93.80 1.05 1.13% 92.75 94.05 92.50
    Nov 10, 2023 92.55 -0.35 -0.38% 92.90 93.25 91.35
    Nov 9, 2023 93.20 0.70 0.76% 92.50 93.90 92.45
    Nov 8, 2023 92.90 0.80 0.87% 92.10 93.65 92.10

    Biomerieux Events

    Time (UTC) Country Event
    Wednesday, March 6, 2024

    Time (UTC)

    07:30

    Country

    FR

    Event

    Full Year 2023 Biomerieux SA Earnings Release
    Full Year 2023 Biomerieux SA Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 3589.1 3376.2 3118.2 2674.8 2421.3
    Revenue 3589.1 3376.2 3118.2 2674.8 2421.3
    Cost of Revenue, Total 1580.4 1375.4 1364.5 1208.2 1119
    Gross Profit 2008.7 2000.8 1753.7 1466.6 1302.3
    Total Operating Expense 3001.9 2591.3 2566 2304.1 2075.2
    Selling/General/Admin. Expenses, Total 954.7 815.6 789.3 749.8 643.1
    Research & Development 446.6 385.8 398.8 374.3 326.9
    Depreciation / Amortization 76.6 59.7 17.5 17.9 17.5
    Unusual Expense (Income) -0.6 0.6
    Other Operating Expenses, Total -56.4 -44.6 -4.7 -46.1 -31.3
    Operating Income 587.2 784.9 552.2 370.7 346.1
    Interest Income (Expense), Net Non-Operating -4.3 -11.7 -29.1 -23.8 -26.7
    Other, Net -2.3 1.3 1.2 0.7 -1.9
    Net Income Before Taxes 580.6 774.5 524.3 347.6 317.5
    Net Income After Taxes 440.5 598.9 402.8 269.8 252.4
    Minority Interest 11.8 2.9 1.7 3.1 1.1
    Equity In Affiliates 0 -0.7 -0.2 0 0.2
    Net Income Before Extra. Items 452.3 601.1 404.3 272.9 253.7
    Net Income 452.3 601.1 404.3 272.9 253.7
    Total Adjustments to Net Income 0.1 0 0.1 -0.1 2.8
    Income Available to Common Excl. Extra. Items 452.4 601.1 404.4 272.8 256.5
    Income Available to Common Incl. Extra. Items 452.4 601.1 404.4 272.8 256.5
    Diluted Net Income 452.4 601.1 404.4 272.8 256.5
    Diluted Weighted Average Shares 118.441 118.893 118.592 118.609 118.203
    Diluted EPS Excluding Extraordinary Items 3.81964 5.05579 3.41 2.3 2.17
    Dividends per Share - Common Stock Primary Issue 0.85 0.85 0.62 0.19 0.35
    Diluted Normalized EPS 3.81964 5.05189 3.41389 2.3 2.17
    Dilution Adjustment 0
    Jun 2023 Dec 2022 Jun 2022 Dec 2021 Jun 2021
    Total revenue 1770.1 1931.1 1658 1802 1574.2
    Revenue 1770.1 1931.1 1658 1802 1574.2
    Cost of Revenue, Total 770.9 860.4 720 721.6 659.2
    Gross Profit 999.2 1070.7 938 1080.4 915
    Total Operating Expense 1562.3 1641 1360.9 1383.5 1208.4
    Selling/General/Admin. Expenses, Total 502.1 514.4 440.3 436.9 379.6
    Research & Development 226.5 239.3 207.3 204.8 181.5
    Depreciation / Amortization 83.6 51.7 24.9 44.6 8.3
    Other Operating Expenses, Total -20.8 -24.8 -31.6 -24.4 -20.2
    Operating Income 207.8 290.1 297.1 418.5 365.8
    Interest Income (Expense), Net Non-Operating 0.9 2.8 -7.1 -4.7 -7
    Other, Net -0.4 -3.8 1.5 1.3 0.6
    Net Income Before Taxes 208.3 289.1 291.5 415.1 359.4
    Net Income After Taxes 138.7 214.2 226.3 322 276.9
    Minority Interest 22.9 10 1.8 1.8 1.1
    Equity In Affiliates 0 0 0 0.2 -0.9
    Net Income Before Extra. Items 161.6 224.2 228.1 324 277.1
    Net Income 161.6 224.2 228.1 324 277.1
    Income Available to Common Excl. Extra. Items 161.6 224.4 228 324 277.1
    Income Available to Common Incl. Extra. Items 161.6 224.4 228 324 277.1
    Diluted Net Income 161.6 224.4 228 324 277.1
    Diluted Weighted Average Shares 118.613 118.533 118.349 119.1 118.927
    Diluted EPS Excluding Extraordinary Items 1.36241 1.89315 1.92651 2.7204 2.33
    Dividends per Share - Common Stock Primary Issue 0 0.85 0 0.85 0
    Diluted Normalized EPS 1.36241 1.89315 1.92651 2.7204 2.33
    Total Adjustments to Net Income 0.2 -0.1 0
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 2216.7 2184.6 1661.6 1438.5 1314.4
    Cash and Short Term Investments 552.6 803.5 389.2 275 288.3
    Cash 401.7 547.1 313.5 241 239.9
    Cash & Equivalents 150.9 256.4 75.7 34 48.4
    Total Receivables, Net 926.9 761 730.4 668.8 607.3
    Accounts Receivable - Trade, Net 740.1 590.6 597.9 552.1 491.8
    Total Inventory 737.2 620 541.9 494.7 418.8
    Other Current Assets, Total 0.1 0.1
    Total Assets 5186.6 4605 3927.8 3781.9 3501.6
    Property/Plant/Equipment, Total - Net 1369.9 1224.8 1068.6 1025.2 899.1
    Property/Plant/Equipment, Total - Gross 2703.9 2447.7 2173.3 2100.9 1899.4
    Accumulated Depreciation, Total -1334.1 -1222.7 -1104.7 -1075.7 -1000.5
    Goodwill, Net 812.5 669.5 629.4 652.5 619
    Intangibles, Net 625 411.5 430.7 508.4 507.2
    Long Term Investments 71.2 62 39.9 31.7 59.2
    Note Receivable - Long Term 19.8 10.7 10.4 8
    Other Long Term Assets, Total 71.5 52.6 86.9 115.2 94.7
    Total Current Liabilities 1131.1 955.7 923.8 1170.1 796.3
    Accounts Payable 269.4 239.5 207.1 211.9 179.7
    Accrued Expenses 372.6 327.4 283.3 262.4
    Notes Payable/Short Term Debt 23.9 0 0 0 0
    Current Port. of LT Debt/Capital Leases 163.1 99.7 128.9 438.6 129.1
    Other Current Liabilities, Total 302.1 616.5 260.4 236.3 225.1
    Total Liabilities 1582.4 1492.8 1496.7 1578 1572.8
    Total Long Term Debt 318.4 362.8 352.4 153.7 524.9
    Long Term Debt 224.7 362.8 352.4 153.7 524.9
    Deferred Income Tax 53 60.3 105.8 141.2 130.5
    Minority Interest 38.7 51.4 50.2 50.7 74.1
    Other Liabilities, Total 41.2 62.6 64.5 62.3 47
    Total Equity 3604.2 3112.2 2431.1 2203.9 1928.8
    Common Stock 12 12 12 12 12
    Additional Paid-In Capital 3062.2 2532.1 2204.7 1933.4 1712.2
    Retained Earnings (Accumulated Deficit) 410.4 542.5 344.7 207.9 210.1
    Treasury Stock - Common -36 -10.3 -23 -3.9 -32.8
    Other Equity, Total 155.6 35.9 -107.3 54.5 27.3
    Total Liabilities & Shareholders’ Equity 5186.6 4605 3927.8 3781.9 3501.6
    Total Common Shares Outstanding 118 118.282 118.16 118.324 117.819
    Capital Lease Obligations 93.7
    Jun 2023 Dec 2022 Jun 2022 Dec 2021 Jun 2021
    Total Current Assets 2152.7 2216.7 2058.4 2184.6 1798.7
    Cash and Short Term Investments 423 552.6 524.2 803.5 493.2
    Cash 320.2 401.7 365.6 803.5 363.3
    Cash & Equivalents 102.8 150.9 158.6 129.9
    Total Receivables, Net 888.9 926.9 825.7 761 694.5
    Accounts Receivable - Trade, Net 657.7 740.1 624.2 590.6 542.4
    Total Inventory 840.9 737.2 708.5 620 611
    Total Assets 5030.9 5186.6 5041.2 4605 4157.2
    Property/Plant/Equipment, Total - Net 1392 1369.9 1314.4 1224.8 1135.2
    Property/Plant/Equipment, Total - Gross 2782.4 2703.9 2620.7 2447.7 2306.1
    Accumulated Depreciation, Total -1390.4 -1334 -1306.2 -1222.7 -1170.8
    Goodwill, Net 734.4 812.5 877.5 669.5 642.4
    Intangibles, Net 592.5 625 667.5 411.5 426.8
    Long Term Investments 89.2 91 48 62 56.6
    Other Long Term Assets, Total 70.1 71.5 75.4 52.6 97.5
    Total Current Liabilities 980.7 1131.1 1020.7 955.7 857.9
    Accounts Payable 243.5 269.4 243.4 239.5 199.1
    Notes Payable/Short Term Debt 22.4 23.9 11 0 0
    Current Port. of LT Debt/Capital Leases 138.2 163.1 215 99.7 163.2
    Other Current Liabilities, Total 576.6 674.7 551.3 616.5 495.6
    Total Liabilities 1403.6 1582.4 1572.2 1492.8 1459
    Total Long Term Debt 330.1 318.4 365.7 362.8 361.5
    Long Term Debt 231.7 224.7 272 362.8 361.5
    Deferred Income Tax 33.9 53 97.2 60.3 124.7
    Minority Interest 14.2 38.7 44.9 51.4 50.8
    Other Liabilities, Total 44.7 41.2 43.7 62.6 64.1
    Total Equity 3627.3 3604.2 3469 3112.2 2698.2
    Common Stock 12 12 12.2 12 12
    Additional Paid-In Capital 3416.3 3062.2 3174.3 2532.1 2528.8
    Retained Earnings (Accumulated Deficit) 120.2 410.4 183.5 542.5 219.5
    Treasury Stock - Common -20.9 -36 -152.3 -10.3 -16.6
    Other Equity, Total 99.7 155.6 251.3 35.9 -45.5
    Total Liabilities & Shareholders’ Equity 5030.9 5186.6 5041.2 4605 4157.2
    Total Common Shares Outstanding 118.124 118 119.507 118.282 118.095
    Other Current Assets, Total -0.1 0.1
    Capital Lease Obligations 98.4 93.7 93.7
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line 440.5 598.2 402.7 269.7 255.6
    Cash From Operating Activities 475.1 824.7 582.8 407.9 399.7
    Cash From Operating Activities 67 58.8 210.8 189.5 177
    Non-Cash Items 264.8 176.7 159 45.5 12.3
    Cash Taxes Paid 223.5 185.4 115.9 81.6 66.5
    Cash Interest Paid
    Changes in Working Capital -297.2 -9 -189.7 -96.8 -45.2
    Cash From Investing Activities -528.1 -307.3 -265.2 -282.2 -413.1
    Capital Expenditures -286.7 -290.1 -277.5 -272.5 -226.4
    Other Investing Cash Flow Items, Total -241.4 -17.2 12.3 -9.7 -186.7
    Cash From Financing Activities -244.2 -140.6 -176.2 -133.9 43
    Financing Cash Flow Items -0.1 -2.4 -23.4 0
    Total Cash Dividends Paid -101.2 -73.1 -22.5 -41.3 -40.2
    Issuance (Retirement) of Stock, Net -157.2 -17.4 -16.8 0 -22.3
    Issuance (Retirement) of Debt, Net 14.3 -50.1 -134.5 -69.2 105.5
    Foreign Exchange Effects 38.7 39.2 -34.1 -6.1 -11.8
    Net Change in Cash -258.5 416 107.3 -14.3 17.8
    Dec 2022 Jun 2022 Dec 2021 Jun 2021
    Net income/Starting Line 440.5 226.2 598.2 276
    Cash From Operating Activities 475.1 150.9 824.7 285.8
    Cash From Operating Activities 67 100.4 58.8 97.2
    Non-Cash Items 264.8 -27.4 176.7 -66.4
    Cash Taxes Paid 223.5 145.4 185.4 98.1
    Changes in Working Capital -297.2 -148.3 -9 -21
    Cash From Investing Activities -528.1 -352.3 -307.3 -143.4
    Capital Expenditures -286.7 -152.8 -290.1 -143.5
    Other Investing Cash Flow Items, Total -241.4 -199.5 -17.2 0.1
    Cash From Financing Activities -244.2 -127.8 -140.6 -73.8
    Total Cash Dividends Paid -101.2 -101.2 -73.1 -73.1
    Issuance (Retirement) of Stock, Net -157.2 -111.3 -17.4 -2.5
    Issuance (Retirement) of Debt, Net 14.3 84.8 -50.1 1.8
    Foreign Exchange Effects 38.7 55.2 39.2 12.8
    Net Change in Cash -258.5 -274 416 81.4
    Financing Cash Flow Items -0.1 -0.1
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Mérieux Family Other Insider Investor 58.9047 69720270 0 2022-12-13
    Dassault Family Other Insider Investor 4.5964 5440410 0 2022-12-13 LOW
    Sofina S.A. Investment Advisor/Hedge Fund 1.7293 2046857 0 2022-12-13
    Oddo BHF Asset Management S.A.S Investment Advisor/Hedge Fund 1.356 1604994 44775 2023-09-30 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 1.0518 1244911 5637 2023-09-30 LOW
    Candriam Luxembourg S.A. Investment Advisor 0.877 1037976 -63467 2023-09-30 MED
    Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 0.853 1009582 -23564 2022-12-31 LOW
    Biomérieux Employees Corporation 0.7268 860200 0 2022-12-13
    DNCA Investments Investment Advisor 0.6872 813349 178315 2023-09-30 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 0.6085 720178 -7576 2023-09-30 LOW
    Amundi Asset Management, SAS Investment Advisor/Hedge Fund 0.5764 682229 3853 2023-09-30 LOW
    Devon Equity Management Ltd. Investment Advisor 0.5669 670995 0 2023-09-30 LOW
    La Financière de l'Echiquier Investment Advisor 0.5363 634787 -66095 2023-09-30 MED
    Capital Research Global Investors Investment Advisor 0.5084 601782 -4401 2023-09-30 LOW
    BlackRock Advisors (UK) Limited Investment Advisor/Hedge Fund 0.4926 583078 6150 2023-09-30 LOW
    CPR Asset Management Investment Advisor 0.4043 478520 -2462 2023-08-31 MED
    AXA Investment Managers Paris Investment Advisor/Hedge Fund 0.3672 434670 -4318 2023-08-31 LOW
    BlackRock Investment Management (UK) Ltd. Investment Advisor/Hedge Fund 0.3641 430947 2514 2023-08-31 LOW
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.3628 429455 1 2023-09-30 LOW
    Credit Mutuel Asset Management Investment Advisor 0.3119 369132 3000 2023-08-31 MED

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Biomerieux Company profile

    About BioMerieux SA

    Biomerieux SA is a France-based company that specializes in the field of in-vitro diagnostics for medical and industrial applications. The Company designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial applications, such as for the analysis of industrial or environmental samples. The Company also provides its customers with related services for the installation and maintenance of instruments, and training for product users. BioMerieux SA operates through its numerous subsidiaries in various countires, including bioMerieux Deutschland GmbH, bioMerieux Austria GmbH, Advencis, bioMerieux Benelux SA/NV, as well as BioFire Diagnostics Inc., chromID CARBA SMART and new bi-plate Petri dish.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, BioMerieux SA revenues increased 8% to EUR3.38B. Net income applicable to common stockholders increased 49% to EUR601.1M. Revenues reflect Microbiology segment increase of 12% to EUR1.06B, Molecular Biology segment increase of 5% to EUR1.27B, Europe & Middle East & Africa (EMEA) (Region) segment increase of 10% to EUR1.12B, America segment increase of 5% to EUR1.67B.

    Equity composition

    9/2017, 3-for-1 stock split (Factor: 3).

    Industry: Laboratory Diagnostic & Testing Substances

    376, chemin de l'Orme
    CRAPONNE
    AUVERGNE-RHONE-ALPES 69280
    FR

    Income Statement

    • Annual
    • Quarterly

    News

    December RBA preview: no move expected at the final meeting of 2023

    The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

    14:47, 4 December 2023

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023

    People also watch

    Oil - Crude

    72.55 Price
    -1.200% 1D Chg, %
    Long position overnight fee -0.0227%
    Short position overnight fee 0.0007%
    Overnight fee time 22:00 (UTC)
    Spread 0.040

    US100

    15,958.50 Price
    +0.850% 1D Chg, %
    Long position overnight fee -0.0263%
    Short position overnight fee 0.0041%
    Overnight fee time 22:00 (UTC)
    Spread 1.8

    Gold

    2,022.41 Price
    -0.330% 1D Chg, %
    Long position overnight fee -0.0198%
    Short position overnight fee 0.0116%
    Overnight fee time 22:00 (UTC)
    Spread 0.30

    BTC/USD

    43,765.00 Price
    +4.040% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading